Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging ...

CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for ...
Stocktwits on MSN

CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal?

CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec. 10, 2025 ...
TipRanks on MSN

Corbus Pharmaceuticals reports results from Phase 1a study of CRB-913 in obesity

Corbus Pharmaceuticals (CRBP) announced the completion of the single ascending dose, or SAD, and multiple ascending dose, or ...

Corbus Pharmaceuticals stock rises after promising obesity drug safety data

Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock rose 5% after reporting positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist being developed for ...
CSR Wire

CRB Board of Directors Adds CEO Title to President Ryan Schroeder; Company Announces Sam Kitchell as New Chief Operating Officer

KANSAS CITY, Mo., March 29, 2023 /CSRwire/ - CRB, a leading global provider of sustainable engineering, architecture, construction, and consulting solutions to the biopharmaceutical and food and ...
The Manila Times

CRB welcomes Tyler Manker as Senior Project Director, Preconstruction, for Food and Beverage

Tyler Manker has joined CRB as Senior Project Director, Preconstruction, within the company's Food & Beverage business. With nearly two decades of engineering and construction leadership, Manker ...